KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 2

Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders

Ümit Özgür AKDEMİR
Lütfiye Özlem ATAY
Ayşe BORA TOKÇAER
Sayfa
400–410
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This review covers the rationale of using DAT SPECT imaging in the diagnosis of PD and other parkinsonian disorders, specifically focusing on the practical aspects of imaging and routine clinical indications.Key words: Dopamine transporter, 123I-ioflupane, SPECT, Parkinson’s disease, parkinsonian disorders

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Abstract: The dopamine transporter (DAT) imaging provides an objective tool for the assessment of dopaminergic function of presynaptic terminals which is valuable for the differential diagnosis of parkinsonian disorders related to a striatal dopaminergic deficiency from movement disorders not related a striatal dopaminergic deficiency.
📊
Temel Bulgular & Veri:DAT imaging with single-photon emission computed tomography (SPECT) can be used to confirm or exclude a diagnosis of dopamine deficient parkinsonism in cases where the diagnosis is unclear.
💡
Sonuç & Katkı:This review covers the rationale of using DAT SPECT imaging in the diagnosis of PD and other parkinsonian disorders, specifically focusing on the practical aspects of imaging and routine clinical indications.Key words: Dopamine transporter, 123I-ioflupane, SPECT, Parkinson’s disease, parkinsonian disorders
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Abstract: The dopamine transporter (DAT) imaging provides an objective tool for the assessment of dopaminergic function of presynaptic terminals which is valuable for the differential diagnosis of parkinsonian disorders related to a striatal dopaminergic deficiency from movement disorders not related a striatal dopaminergic deficiency. DAT imaging with single-photon emission computed tomography (SPECT) can be used to confirm or exclude a diagnosis of dopamine deficient parkinsonism in cases where the diagnosis is unclear. It can also detect the dopaminergic dysfunction in presymptomatic subjects at risk for Parkinson’s disease (PD) since the reduced radiotracer binding to DATs in striatum is already present in the prodromal stage of PD. This review covers the rationale of using DAT SPECT imaging in the diagnosis of PD and other parkinsonian disorders, specifically focusing on the practical aspects of imaging and routine clinical indications.Key words: Dopamine transporter, 123I-ioflupane, SPECT, Parkinson’s disease, parkinsonian disorders

🔖

Bu Makaleye Atıf Yap

AKDEMİR, Ü. Ö., ATAY, L. Ö., TOKÇAER, A. B. (2022). Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 2, 400–410. https://ajindex.com/articles/609429

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Palermo G, Ceravolo R. Molecular imaging of the dopamine transporter. Cells 2019
  2. 8 (8): 872. doi: 10.3390/cells8080872 2. Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. Metabolism-Clinical and Experimental 2015
  3. 64 (3): S40-S46. doi: 10.1016/j.metabol.2014.10.030 3. Fazio P, Svenningsson P, Cselenyi Z, Halldin C, Farde L et al. Nigrostriatal dopamine transporter availability in early Parkinson’s disease. Movement Disorders 2018
  4. 33 (4): 592-599. doi: 10.1002/mds.27316 4. Brooks DJ. Molecular imaging of dopamine transporters. Ageing Research Reviews 2016
  5. doi: 10.1016/j. arr.2015.12.009 5. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2010
  6. 37 (2): 443-450. doi: 10.1007/s00259-009- 1267-x 6. Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging 2020
  7. 47 (8): 1885-1912. doi: 10.1007/s00259-020-04817-8 7. Akdemir ÜÖ, Atay LÖ, Aydın F, Çakır T, Kaya M et al. Parkinsonyen sendromlarda dopaminerjik görüntüleme kılavuzu. Nuclear Medicine Seminars 2020
  8. 2 (6): 243-255 (in Turkish). doi: 10.4274/nts.galenos.2020.0019 8. Subramaniam RM, Frey KA, Hunt CH, Mercier GA Jr., Solnes LB et al. ACR-ACNM practice parameter for the performance of dopamine transporter (DaT) single photon emission computed tomography (SPECT) imaging for movement disorders. Clinical Nuclear Medicine 2017
  9. 42 (11): 847-852. doi: 10.1097/ RLU.0000000000001815 9. Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. Journal of Nuclear Medicine 2012
  10. 53 (1): 154-163. doi: 10.2967/jnumed.111.100784 10. Van Laere K, Varrone A, Booij J, Vander Borght T, Nobili F et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2010
  11. 37 (2): 434-442. doi: 10.1007/s00259-009-1265-z 11. Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH et al. [(1) (8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012
  12. 79 (13): 1314-1322. doi: 1